Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Vanguard Total Stock Market Index Fund ETF trades at $367.69. Which is the better fit depends on your goals.
| ABEO | VTI | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $374.36 |
52-Week Low | $4.17 | $305.58 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VTI trades at $371.67, up 0.79% today, with a bullish technical outlook supported by moving averages. The ETF offers broad U.S. equity exposure across 3,400+ stocks with a minimal 0.03% expense ratio. Recent news highlights its inclusion in new Trump Accounts and comparisons with competing total market ETFs, reinforcing its popularity for long-term wealth building.
VTI presents a low-cost core holding for diversified U.S. stock exposure, though its neutral oscillators and elevated short-term RSI suggest near-term consolidation risks. Market volatility and economic shifts remain key headwinds, but analyst sentiment favors its long-term growth potential amid accelerating small-cap earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
